DEFC14A: Dynavax Faces Proxy Fight as Deep Track Capital Nominates Opposing Board Slate

Dynavax Technologies is urging stockholders to vote for its board nominees and against a stockholder proposal from Deep Track Capital at the upcoming annual meeting.

Summary

• Dynavax Technologies Corporation is holding its 2025 Annual Meeting of Stockholders virtually on June 11, 2025.
• The board is recommending stockholders vote for its four nominees for Class I director positions: Brent MacGregor, Scott Myers, Lauren Silvernail, and Elaine Sun.
• A stockholder, Deep Track Capital, has nominated four opposing candidates and proposed a bylaw amendment.
• The board is urging stockholders to reject Deep Track's nominees and proposal.
• Key achievements in 2024 included record HEPLISAV-B product revenue of $268.4 million, a 26% increase from 2023, and adjusted EBITDA of $51.9 million, a 329% increase from 2023.
• The company expects HEPLISAV-B net product revenue of $305.0 to $325.0 million and adjusted EBITDA of at least $75.0 million in 2025.
• The board is seeking stockholder approval to declassify the board, transitioning to annual elections for all directors beginning in 2026.
• The board authorized a $200.0 million share repurchase program, with $100.0 million already repurchased through an Accelerated Share Repurchase agreement and approximately $8.0 million repurchased in conjunction with a recent debt refinancing.
• The company refinanced a majority of its outstanding Convertible Senior Notes, extending the maturity date and lowering the overall cost of capital.
• A Phase 1/2 clinical trial for the shingles vaccine program, Z-1018, is expected to have a clinical trial readout in the third quarter of 2025.
• The company completed a Phase 2 clinical trial for a plague vaccine candidate adjuvanted with CpG 1018, securing $30.0 million in additional funding from the U.S. Department of Defense through the first half of 2027.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Dynavax, highlighting strong financial performance and pipeline progress. However, the proxy contest introduces uncertainty, slightly tempering the overall sentiment.

Positives

• Record HEPLISAV-B product revenue and increased market share.
• Significant increase in adjusted EBITDA.
• Share repurchase program authorized and executed.
• Successful debt refinancing.
• Advancement of pipeline programs, including the shingles and plague vaccine candidates.
• Strong cash balance of $713.8 million at year-end 2024.
• Commitment to corporate governance and board refreshment with the addition of two new directors.

Negatives

• A proxy contest initiated by Deep Track Capital, creating uncertainty and requiring management attention.
• The company did not achieve its U.S. sales target of $275.0 million for HEPLISAV-B, achieving $268.0 million.
• The company did not achieve its fourth quarter total U.S. market share target of greater than 47%, achieving 44%.

Risks

• The proxy contest with Deep Track Capital could divert management's attention and resources.
• Failure to achieve projected revenue and EBITDA targets for 2025.
• Risks inherent in the development and commercialization of new vaccine products.
• Dependence on the success of HEPLISAV-B and the CpG 1018 adjuvant technology.
• Potential impact of competition and market dynamics on HEPLISAV-B sales.
• The aspirational nature of ESG strategies and initiatives, which are not guarantees or promises that such strategies and initiatives will be realized or will otherwise result in the anticipated benefits to Dynavax and/or its stakeholders.

Future Outlook

The company expects HEPLISAV-B net product revenue of $305.0 to $325.0 million and adjusted EBITDA of at least $75.0 million in 2025. The company anticipates reporting top line immunogenicity and safety data from the shingles vaccine trial in the third quarter of 2025.

Management Comments

• Our performance in 2024 sets us up for even greater success in 2025, which we expect to be another banner year for Dynavax and we are already making important progress to achieve our 2025 guidance targets, including HEPLISAV-B net product revenue of $305.0 to $325.0 million and adjusted EBITDA of at least $75.0 million.
• We believe this refinancing significantly strengthens our capital structure and positions us to execute on our balanced strategy to deliver and protect near-term value while also investing in our future to drive long-term growth.
• We expect 2025 to be a transformational year for our pipeline with multiple programs advancing to important milestones, including a clinical trial readout for our shingles vaccine program, which has the potential to be a best-in-class product in a multi-billion-dollar global market.

Industry Context

The company is operating in the vaccine market, focusing on hepatitis B, shingles, and plague. The announcement highlights the company's efforts to expand its market share and advance its pipeline programs, positioning itself as a leading vaccine company.

Comparison to Industry Standards

• The company's HEPLISAV-B vaccine competes with other hepatitis B vaccines in the market.
• The shingles vaccine program, Z-1018, is being developed as a potential best-in-class product in a multi-billion-dollar global market, competing with existing vaccines like Shingrix.
• The company's CpG 1018 adjuvant technology is being leveraged to develop differentiated vaccine candidates, potentially offering advantages over traditional vaccine approaches.
• The company's financial performance is being compared to other biotechnology companies in its peer group, with a focus on revenue growth, EBITDA, and capital allocation.

Management Changes

Corporate Governance

Stakeholder Impact

• Stockholders: Impacted by the proxy contest, board composition, and company performance.
• Employees: Affected by compensation programs, training, and community involvement initiatives.
• Customers: Benefit from the development and commercialization of new vaccines.
• Suppliers: Impacted by the company's manufacturing and supply chain operations.
• Creditors: Affected by the company's financial performance and debt refinancing.

Next Steps

• Stockholders to vote on director nominees and other proposals at the Annual Meeting on June 11, 2025.
• Company to continue executing its strategic plan, including driving HEPLISAV-B growth and advancing pipeline programs.
• Company to report top line immunogenicity and safety data from the shingles vaccine trial in the third quarter of 2025.

Key Dates

Keywords

Dynavax, HEPLISAV-B, vaccine, Deep Track Capital, proxy contest, board of directors, stockholders, adjusted EBITDA, share repurchase, CpG 1018 adjuvant, shingles vaccine, plague vaccine, corporate governance